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E-mail address: gsimmons@bloodsystems.org (G. SSevere acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an
endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising
potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug
against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process pro-
vides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-
throughput screening system, dual envelope pseudovirion (DEP) assay, for specifically screening inhibi-
tors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudoviri-
ons as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral
envelope is used as an internal control to reduce the number of false positives. As an example of the
power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps
of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to
screen entry inhibitors against other viruses with the careful selection of matching partner virus
envelopes.
 2011 Elsevier B.V. All rights reserved.1. Introduction with many of these candidates failing to inhibit viral replicationSARS-CoV is an emerging pathogen responsible for a global out-
break of atypical pneumonia between 2002 and 2003 (WHO,
2003). Although a number of promising potential vaccines and
therapeutic agents for SARS-CoV have been described (reviewed
in Golda and Pyrc, 2008), it is unclear if any are likely to become
therapeutically useful. In particular, although neutralizing mono-
clonal antibodies have been identified (Rockx et al., 2008), the
diversity of SARS-CoV-like sequences found in the animal reser-
voirs makes antigen selection for vaccine development difficult
prior to a new zoonotic transmission (Deming et al., 2006; Liu
et al., 2007).
A number of stages in the SARS-CoV life cycle represent attrac-
tive targets for potential anti-SARS-CoV therapeutics. Enzymatic
processes such as polymerase and protease activity are often good
targets for antivirals due to their specialized mode of action. Trials
using small animal models, however, have been less promisingll rights reserved.
search Institute, 270 Masonic
0748; fax: +1 415 567 5899.
immons).in vivo (Barnard et al., 2006). Inhibition of viral entry is appealing
as a drug target for many viruses including SARS-CoV as it prevents
the initiation of any steps towards viral replication. Indeed, virus
entry is now a major focus for drug development, with several
inhibitors either on the market or in clinical trials. Multiple steps
in the entry process are valid targets for inhibition, including
attachment, receptor engagement, viral internalization, envelope
conformational rearrangements and membrane fusion. The use of
pseudovirions to identify small molecule entry inhibitors of diffi-
cult to handle and/or highly pathogenic BSL 3/4 viruses such as
Lassa virus has recently been described (Garcia et al., 2009; Larson
et al., 2008; York et al., 2008). Indeed, using pseudovirions, com-
plemented with live virus, we have previously demonstrated that
inhibitors of cysteine proteases, such as leupeptin, act as potent
inhibitors of SARS-CoV entry (Simmons et al., 2005). This inhibition
is the result of an absolute requirement in cell lines for endosomal
processing of the spike glycoprotein by cathepsin L (CTSL) during
entry into the target cell (Simmons et al., 2005, 2011). In vivo,
the situation is more complicated, with a number of secreted or
surface proteases presence in the respiratory tract, such as the
cellular type II transmembrane serine protease (TTSP) TMPRSS2,
188 Y. Zhou et al. / Antiviral Research 92 (2011) 187–194able to mediate SARS-CoV entry via non-endosomal routes (Glowa-
cka et al., 2011; Kam et al., 2009).
We describe here a rapid and safe cell-based high-throughput
screening (HTS) assay system for specifically screening inhibitors
of viral entry, using lentiviral pseudovirions whose entry is driven
by SARS-CoV Spike glycoprotein. In preliminary studies, we found
that many initial hits identified as potential inhibitors of entry
mediated by enveloped, pH-dependent viruses such as SARS-CoV,
were mildly toxic in at least some cell lines. These candidate inhib-
itors were also often able to inhibit many other enveloped viruses,
likely due to subtle effects on cellular function such as endocytosis
(data not shown). In order to overcome this obstacle at an early
stage, a second unrelated viral envelope was utilized in order to
reduce the numbers of false positive hits obtained from the
primary screen. Both targeted and general small molecule libraries
were screened for inhibitors of SARS-CoV entry, and a number of
compounds were identified that inhibit SARS-CoV entry and
replication.2. Materials and methods
2.1. Cells and reagents
Human embryonic kidney 293T cells, clone 17 (293T/17) were
obtained from the ATCC and grown in Dulbecco’s Modified Eagle
Medium (DMEM; Invitrogen) supplemented with 10% FBS and
penicillin and streptomycin (10 U/ml). 293T/17 stably expressing
human angiotensin converting enzyme 2 (293T/ACE2) were estab-
lished by transfecting 293T/17 cells with pcDNA6 (Invitrogen)
encoding the ACE2 gene and selecting for stable transformants
using blasticidin S (2.5 lg/ml).
Control inhibitors included 30-azido-20,30-dideoxythymidine
(AZT; Sigma–Aldrich) as an inhibitor of all pseudovirions, leupeptin
and Z-Phe-Phe-FMK (EMD Biosciences) as inhibitors of SARS-CoV
entry, ST-193 (Larson et al., 2008) for Lassa, and anti-murine leuke-
mia virus (MLV) antibody for inhibition of MLV (a gift from Dr.
Leonard Evans, Rocky Mountain Laboratories).
2.2. Plasmids and gene constructs
Pseudotyped viruses were generated from two plasmids, one
encoding the envelope and the other encoding the viral backbone
with a reporter gene. Plasmids encoding SARS-CoV spike glycopro-
tein, Ebola GP, vesicular stomatitis virus (VSV)-G, chikungunya
virus (CHIKV), as well as MLV envelope, have been described
(Gilbert et al., 1994; Salvador et al., 2009; Simmons et al., 2002,
2004, 2005). The Lassa GP gene was synthesized based on the
sequence of strain GA391, and subcloned into pcDNA3.1.
The envelope-deficient HIV reporter construct, pNL4-3
Luc-RE (pNL-luc), encodes a replication-incompetent variant of
the HIV-1 molecular clone NL4-3, in which the nef gene has been
replaced by a firefly luciferase (luc) reporter, and the env and vpr
genes were inactivated, as previously described (Connor et al.,
1995). Similarly, pNL4-3.ren.RE was constructed by swapping
the firefly luciferase gene for Renilla luciferase using NotI and XhoI.
2.3. Pseudovirion production and titration
Pseudovirions were produced essentially as previously de-
scribed (Simmons et al., 2004). Briefly, 293T/17 cells were transfec-
ted with 30 lg of viral envelope encoding plasmid and 10 lg of
pNL4-3 reporter backbone per 10-cm dish by using calcium phos-
phate. The next day, expression was induced with sodium butyrate
(10 mM) for 6 h before washing once. Forty hours after transfec-
tion, supernatant was filtered through a 0.45 lm-pore-size filterand frozen at 80 C. Resulting reporter viruses were classified
according to reporter system and viral envelope, for example
HIV-luc(SARS-CoV S) or HIV-ren(Lassa GP). Virus was titrated using
the same conditions described below for the screening assays.
2.4. Libraries and compounds
A 2000+ compound library of diverse candidate cysteine prote-
ase inhibitors collected from a range of academic and industry
sources and curated at UCSF Sandler Center for Drug Discovery
as previously described (Goetz et al., 2007) was screened. A general
small molecule compound library purchased from ChemDiv and
curated at UCSF Small Molecule Discovery Core was also screened.
WRR-182, WRR-183 and WRR485-WRR496 were synthesized
as previously described (Goetz et al., 2007; Roush et al., 1998).
Each synthetic inhibitor had a purity of >95%, as determined by
NMR analysis, except for WRR-493 that was isolated and tested
as an inseparable mixture of epoxide diastereomers.
2.5. 96-well and 384-well screening assays
High-throughput screens for inhibitors of SARS-CoV-mediated
entry were performed in either 96-well or 384-well formats, using
white tissue culture plates (NUNC). Initial 100% dimethyl sulfoxide
(DMSO) stocks of compounds at 20 mM were used to prepare dilu-
tion plates at 1 mM using 100% DMSO. In the 96-well assay format,
compounds were then further diluted in DMEM with 10% FBS to
give a concentration of 80 lM (8% DMSO). Positive inhibition con-
trols of 80 lM AZT and negative controls of medium alone were
also adjusted to contain 8% DMSO. Ten lL of test compound, AZT
or medium alone were transferred to blank and assay wells using
a Biomek FX-P (Beckman-Coulter). A mixture of the target virus
HIV-luc(SARS-CoV S) and the control virus [i.e., HIV-ren(Lassa
GP) or HIV-ren(MLV Env)] was made, with the relative does of each
derived empirically to give similar robust levels of reporter expres-
sion. Thirty lL of reporter virus mix was added to each well using a
Matrix WellMate (Thermo Scientific) on the fast setting with
small-bore tubing. 293T/ACE2 cells were removed from tissue cul-
ture dishes using versine, washed and resuspended at 500,000 cells
per milliliter in a sterile bottle with gentle agitation using a mag-
netic stirrer. Using the WellMate, 40 lL of cells were then added
to all wells on the medium setting and standard-bore tubing. Thus,
compounds were used at a final concentration of 10 lM (1% DMSO)
with 20,000 cells per well. Plates were incubated for two days at
37 C/5% CO2 and firefly and Renilla luciferase reporter expression
was determined using the Dual-Glo Luciferase Assay System (Pro-
mega), by sequential addition (WellMate) and luminescence deter-
mination (POLARstar, BMG Labtech) of first 40 lL of luciferase
reagent and then 40 lL of stop-and-glo.
The assay was performed similarly for the 384-well assay for-
mat, except that 10 lL of compounds and controls were delivered
at 50 lM in 5% DMSO, together with 10 lL of reporter virus mix
and 30 lL of 293T/ACE2 cells at 170,000 cells per milliliter. Levels
of viral infection were determined with 30 lL of each component
of the Dual-Glo system. Test runs to determine assay robustness
were performed as above with medium containing DMSO to give
a final assay concentration of 1%.
2.6. Dose response curves
Assays for dose response curves were performed in 96-well
white tissue culture plates (NUNC). Compounds were serially
diluted in medium maintaining a concentration of 8% DMSO. Ten
lL of the test compounds, or medium alone were transferred to
assay wells, followed by 30 lL of either a single virus or a two re-
porter virus mixture, depending on the purpose of the assay, and
Fig. 1. Diagram of experimental design. The assay uses simultaneous infection including a control pseudovirion encoding Renilla luciferase and incorporating an irrelevant
envelope such as MLV envelope. Thus, toxicity and non-specific inhibition can be controlled. Cells were pretreated with inhibitor, followed by equal volumes of HIV-luc
(SARS-CoV S) and HIV-ren (MLV-A Env) and 293T/ACE2 cells. After 48 h, firefly luciferase and Renilla and were analyzed sequentially using a two-step detection system
(Promega, Medison, WI).
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were incubated for two days at 37 C/5% CO2 and firefly and renilla
luciferase reporter expression was determined using the Dual-Glo
Luciferase Assay System (Promega), or detection of firefly lucifer-
ase reporter expression using the Bright-Glo™ Luciferase Assay
System (Promega).
2.7. Cytotoxicity screening
For cell viability assays, cells were seeded in 96-well black
tissue culture plates (Costar) coated with compounds at a final
concentration of 1% DMSO. The quantity of the ATP present in
metabolically active cells was determined with CellTiter-Glo
Luminescent Cell Viability Assay Systems (Promega, Madison, WI).2.8. Data analysis
A standard method of assessing the quality of HTS assays is the
dimensionless calculation, Z prime (Z0). Statistical calculations
were performed in excel and made as follows: Z0 = 1  [(3  stan-
dard deviation (SD) of the maximum signal control + 3  SD of
the minimum signal control)/|(mean of the maximum signal con-
trol mean of the minimum signal control)|]. %CV = 100  (SD/
mean) (Zhang et al., 1999). A Z0 value for each plate of greater than
0.5 is generally a good indication of an adequate assay (Zhang et al.,
1999). Compounds from the primary screens were considered
inhibitory with the luciferase readings of SARS-CoV, but not the
internal control pseudotyped viruses, fell below the pre-defined
cut-off, mean-3SD (m-3SD).
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lated using non-linear regression analysis based on the sigmoidal
dose response equation using PRISM software applied to the per-
cent inhibition and concentration data.
3. Results
3.1. Assay optimization and validation
We have developed a novel dual envelope pseudovirion (DEP)
Assay for screening inhibitors of viral entry. This dual envelope
strategy allows more efficient screening of libraries, and introduces
internal controls into the primary screen (Fig. 1). A wide-range of
parameters were examined and optimized, including plate types,
dispensing methods, timing of cell addition and cell number,
pseudovirion and DMSO concentration (data not shown).
It is possible that interference between the two envelopes could
occur, either to inhibit entry or to overcome inhibition. In order to
verify that this was not the case entry and inhibition of both
pseudoparticle variants were tested separately and in combination
(Table 1). Assays were carried out with different dual pseudovirus
combinations, one encoding a test viral envelope with firefly lucif-
erase reporter [HIV-luc(viral Env)] and the other encoding a control
viral envelope with renilla luciferase [HIV-ren(viral Env)] and then
compared to the individual virus alone. After 48 h, infection of the
pseudovirion particles in terms of relative light units for firefly and
Renilla luciferase were analyzed sequentially. These studies deter-
mined that some envelopes, such as VSV-G are unsuitable for use
in the dual envelope assay. Use with HIV-luc(VSV-G) led to an al-
most universal increase in infection by HIV-ren viruses (Table 1).
Similarly, most HIV-luc viruses were enhanced by HIV-ren(VSV-
G). This was possibly due to the highly fusogenic nature of VSV-
G. It is notable that a number of other more specific combinations
of pseudotyped viruses also appear to be incompatible (Table 1).
For example, the combination of HIV-luc(MLV Env) and HIV-re-
n(SARS-CoV S) yielded only 62.3% and 81.5% infectivity compared
to the single virus controls, respectively, although the inverse
was, respectively, 82.1% and 105.4%. Moreover, the mix of the same
virus with both firefly and Renilla luciferase reporters also showed
decreased infection compared to the single virus alone, especially
for pseudoviruses with SARS-CoV S, MLV Env or Ebola GP. This is
likely due to competition for low levels of receptors between the
viruses with the two different reporters.
We utilized known inhibitors to determine whether inclusion of
a second virus would adversely affect the ability of inhibitors to
specifically block infection. Cysteine protease inhibitors, such as
leupeptin, are highly effective against SARS-CoV entry in cell lines
(Simmons et al., 2005), and ST-193 has recently been identified as
an inhibitor of arenavirus entry (Larson et al., 2008). The dose
response curves for these two inhibitor classes were super-impos-
able for mixed or individual pseudovirion infections (Fig. 2A andTable 1
Assays with different combinations of two pseudovirusesa.
HIV-ren (SARS S) HIV-ren (Lassa GP) HIV-ren (MLV
Luc%b Ren%b Luc% Ren% Luc% R
HIV-luc (SARS S) 46.9 87.7 84.6 100.6 82.1 1
HIV-luc (Lassa GP) 83.4 95.0 92.6 98.2 71.7 1
HIV-luc (MLV Env) 62.3 81.5 179.1 80.1 5.4 5
HIV-luc (VSV G) 91.9 203.1 65.7 116.5 81.8 4
HIV-luc (Ebola GP) 75.6 96.8 90.6 97.8 77.4 1
HIV-luc (ChIKV Env) 76.4 104.6 99.3 89.2 84.0 3
a Data is shown as mean of triplicate measurements. A representative experiment of
b Results of the dual results are presented as percentage of luciferase reading of singlB). Leupeptin exhibited dose-dependent inhibition of SARS-CoV
infection for both HIV-luc(SARS-CoV S) and HIV-ren(SARS-CoV S),
regardless of whether the partner Lassa GP pseudovirion was pres-
ent or not. Thus, the presence of an irrelevant envelope does not
interfere with inhibition by a specific inhibitor. The dose response
curves of SARS-CoV spike with other envelope combinations were
also assessed and found to give similar results to SARS-CoV spike
and Lassa GP, including envelopes from MLV (Fig. 2C and D) and
CHIKV (data not shown). These results indicate that the dual
pseudovirion systems with SARS-CoV, Lassa GP, MLV or CHIKV
were suitable to be used in HTS against inhibitors of SARS-CoV-
mediated entry. These studies also demonstrated that there were
no issues with signal quenching in the dual assay, such as carry-
over of false signal or loss of true signal. Before proceeding to
HTS, we analyzed the performance of our assay system without
adding any compounds. An example of assay evaluation with the
combination of HIV-luc(SARS-CoV S) and HIV-ren(Lassa GP) five
96-well plates indicated that HIV-ren(Lassa GP) the inter-plate
coefficient of variation (CV) was 3.10%, while the Z0 was 0.91. Sim-
ilarly, for HIV-luc(SARS-CoV S), the CV equaled 6.08% with a Z0 of
0.82. Similar results were observed with the 384-well format
[CVHIV-ren (Lassa GP) = 9.93%; Z0 = 0.78 and CVHIV-luc (SARS-CoV
S) = 7.55%; Z0 = 0.78].
3.2. Screening of a compound library for inhibitors of SARS-CoV-
mediated entry
HTS for inhibitors of SARS-CoV-mediated entry was performed
with 96-well or 384-well NUNC plates. Assays were optimized
with final concentration of compounds at 10 lM in 1% DMSO and
a reporter virus mix of [HIV-luc (SARS-CoV S)+HIV-ren (Lassa GP)
or HIV-luc (SARS-CoV S)+HIV-ren (MLV Env)], and 293T/ACE2 cells
at 2  104 cells in each well for 96-well or 5.1  103 cells per well
for 384-well plates.
As a demonstration of the utility of the dual envelope strategy,
an initial screen of a diverse small molecule library (ChemDiv, San
Diego, CA) was conducted at an inhibitor concentration of 10 lM.
In Fig. 3A, for example, 31 candidates out of a total of over 1250
compounds were identified as inhibitors of SARS-CoVmediated en-
try, using a cut-off of the mean minus three standard deviations
(m-3SD), which was approximately the equivalent of a 50% reduc-
tion in infection. This high hit rate is likely representative of the
fact that related compounds were clustered in the library, and in-
deed a number of related ‘‘hits’’ were identified. Nine of the 31 can-
didates had corresponding reductions in Lassa GP pseudovirions
greater than m-3SD and an additional two candidates had reduc-
tions in Lassa GP controls greater than m-2SD. Because we ob-
served less variation in Lassa GP-based pseudovirions in general,
and based on past experience with toxicity we utilized the stricter
criterion for deciding whether a compoundwas pursued for further
evaluation. Thus, the inclusion of the control pseudovirusEnv) HIV-ren (VSV G) HIV-ren (Ebola GP) HIV-ren (ChIKV Env)
en% Luc% Ren% Luc% Ren% Luc% Ren%
05.4 332.3 92.3 61.5 73.7 116.5 96.9
27.4 117.1 91.2 65.9 89.8 82.6 94.9
1.8 725.0 78.8 117.5 83.5 384.9 86.7
21.4 42.4 190.0 110.9 138.8 92.7 174.7
18.0 83.8 103.3 11.8 65.4 91.7 93.9
88.0 117.8 98.8 91.5 119.0 96.9 94.5
at least three experiments is shown.
e virus.
Fig. 2. Inhibition of dual infection assays. Dose response curves for leupeptin (panels A–D), ST-193 (panels A and B) or MLV antibody (panels C and D) with SARS-CoV spike
pseudovirus with or without combination with Lassa GP/MLV Env pseudovirus. Results are presented as percentage of luciferase reading of no drug controls and shown as
mean ± SD of triplicate measurements. A representative experiment of at least three experiments is shown.
Y. Zhou et al. / Antiviral Research 92 (2011) 187–194 191[HIV-ren(Lassa GP)] was found to be useful for avoiding likely non-
specific inhibition by promiscuous inhibitors and reduced the hit
rate by over a third (11 out of 31 were called false positive)
(Fig. 3B).In addition to performing a random screen for small molecule
inhibitors of SARS-CoV entry, we also exploited the fact that we
had previously identified specific aspects of coronavirus entry that
are amenable to inhibition (Simmons et al., 2005, 2011). Inhibitors
Fig. 3. High-throughput screens for inhibitors of SARS-CoV-mediated entry. (A) An example of screening a small molecule library with the viral combination of HIV-luc
(SARS-CoV S) and HIV-ren (Lassa GP). Results are presented as the logarithm (log) of relative light units (luciferase readings) from four 384-well plates. (B) Close-up of the
highlighted area in 3A. Eight compounds that reduced both SARS-CoV S (green symbols) and Lassa GP (brown symbols) mediated entry are boxed together. 5 compounds that
demonstrate reduction of SARS-CoV alone are highlighted by orange circles, and one compounds that reduces only Lassa GP is highlighted by a blue circle.
192 Y. Zhou et al. / Antiviral Research 92 (2011) 187–194of cysteine proteases, and CTSL in particular, are highly effective at
preventing SARS-CoV infection, while being relatively non-toxic
in vitro. Thus, we screened a unique collection of cysteine protease
inhibitors using the 96-well plate format. As expected from the
inhibitor profiles, a large number of the library members were able
to inhibit entry-mediated by SARS-CoV spike in a specific manner.
Candidate inhibitors exhibiting greater than 90% inhibition of the
SARS-CoV S mediated entry but no inhibition against the control
envelope from the initial screens were further studied and dose re-
sponse curves were generated (for an example of dose response
curves from the protease inhibitor library, see Fig. 1).
3.3. Analysis of the selected inhibitor hits of SARS-CoV-mediated entry
A group of dipeptidyl epoxyketone molecules were identified in
the protease inhibitor library screen that demonstrated significant
inhibition of SARS-CoV S-mediated infection (Fig. 4). Interestingly,
this family of compounds had already been selected from a previ-
ous screen of the same library as being potential inhibitors of one
of SARS-CoV’s own proteases, 3Clpro (Goetz et al., 2007). In partic-ular, WRR 182 and WRR 183 both specifically inhibited live SARS-
CoV viral replication by greater than 50% at 10 lM (Goetz et al.,
2007), even though only WRR 183 was highly active against the
viral protease. In our studies, compound WRR 182 specifically
inhibited SARS-CoV entry with an IC50 of less than 0.1 nM
(Fig. 4A and Table 2), over 40-fold more potent than the inhibitor,
Z-Phe-Phe-FMK, which is marketed as being CTSL-specific. WRR
182 is an epoxide-based inhibitor with a P3 L-phenylalanine resi-
due and an R configuration at C-2 of the epoxide group (Table 2).
WRR 183, a C-2 (S) epoxide isomer of WRR 182, was a 300-fold less
potent inhibitor of SARS-CoV S-mediated entry compared to WRR
182 (Fig. 4A and Table 2). Neither of these compounds demon-
strated detectable cytotoxicity, even at 10 lM (data not shown
and Goetz et al., 2007).
A second generation of dipeptidyl-derived inhibitors based on
the scaffolds of the epoxyketones had already been synthesized
as previously described (Goetz et al., 2007) and viral inhibition as-
says were performed (Table 2). It was hoped that a compound
capable of efficiently inhibiting both the viral protease and CTSL
could be identified. A number of compounds retained the ability
Fig. 4. Epoxyketone inhibition of SARS-CoV (panels A and C) and control envelope entry (panels B and D). Results are presented as a percentage of the luciferase reading of no
drug controls and shown as mean ± SD of triplicate measurements. A representative experiment of at least three experiments is shown.
Table 2
WRR182, WRR183 and derivativesa.
Compounds IC50 (nM)b IC90 (nM)c
WRR182 0.09 ± 0.01 2.97 ± 1.12
WRR183 32.84 ± 3.52 715.07 ± 1.34
WRR485 0.82 ± 0.18 43.41 ± 1.31
WRR486 282.52 ± 20.64 >1000
WRR487 >1000 >1000
WRR488 59.83 ± 8.21 437.48 ± 2.09
WRR492 >1000 >1000
WRR493 >1000 >1000
WRR495 3.36 ± 1.06 54.31 ± 1.99
WRR496 50.57 ± 7.22 >1000
CA-074 >1000 >1000
Z-Phe-Phe-FMK 4.47 ± 1.05 156.22 ± 4.20
a Assay were performed in triplicate and the values are representative of three or
more independent experiments.
b IC50: concentration of the compound that produced 50% decrease in SARS-CoV
pseudotyped virus infection in 293T-ACE2 cells, respectively.
c IC90: concentration of the compound that produced 90% decrease in SARS-CoV
pseudotyped virus infection in 293T-ACE2 cells, respectively.
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potent against 3Clpro (Goetz et al., 2007). WRR 495 was found to
inhibit SARS-CoV entry with a respectable IC50 of approximately
3 nM, again somewhat better than the CTSL-specific inhibitor, Z-
Phe-Phe-FMK (Fig. 4C). However, this compound was found to
have greatly increased toxicity with little added anti-viral benefit
(Goetz et al., 2007). Even though no ideal lead candidates with dual
activity have yet been identified it is hoped that further investiga-
tion may yield such a compound.4. Discussion
In this study, we have developed a novel dual pseudovirion-
based HTS assay system with lentiviral pseudotyped particles. This
system focuses on finding inhibitors of the step of viral entry, and
minimizes the risks associated with hazardous viruses, allowing
handling at BSL-2, when specialized BSL-3 facilities would other-
wise be necessary. The DEP assay also identifies grossly toxic com-
pounds and reduces the number of false positive hits introduced by
compounds able to non-specifically inhibit shared cellular func-
tions of many viruses, for example endocytosis. We demonstrate
that this system reduces the number of false positive hits signifi-
cantly, allowing earlier identification of promising inhibitors.Indeed, if envelopes are chosen with care, this assay allows simul-
taneous screening of two unrelated envelopes of interest that can
also act as internal controls for each other.
In earlier screens we found that many promising inhibitors of
entry mediated by pH-dependent viruses such as SARS-CoV, were
able to inhibit other viruses, likely due to toxic or other more sub-
tle effects on cellular function. These hits were often not cytotoxic
in common laboratory cell lines, but showed sufficient signs of tox-
icity in primary cell types such as hepatocytes not to be considered
likely drug candidates (data not shown). Thus, although pan-viral
family antivirals are an attractive goal, we have generally avoided
such leads as a somewhat unrealistic objective, and the dual enve-
lope assay allows the rapid and early identification and elimination
of such compounds. Ironically, notable exceptions to this rule are
the protease inhibitors described in this study. These compounds
act through a very defined mechanism, blocking envelope process-
ing and/or viral capsid uncoating and can clearly be demonstrated
to inhibit filoviruses, coronaviruses, henipaviruses and reoviruses
(Chandran et al., 2005; Ebert et al., 2002; Pager et al., 2006; Pager
and Dutch, 2005; Schornberg et al., 2006; Simmons et al., 2005).
Thus, care must be taken when choosing partner virus envelopes,
not to use envelopes with overlapping functions, receptors or spe-
cific targets. For example, the use of Ebola GP with SARS-CoV S
would have eliminated the detection of the WRR series of com-
pounds, as entry mediated by both viral envelopes is blocked by
CTSL inhibitors. Indeed, the assay could be reversed if a common
entry mechanism were suspected, in order to deliberately search
for specific inhibitors of this mechanism by only selecting hits that
reduced both viruses.
Based on this assay system, we successfully initiated screens of
two libraries for compounds that would target the viral entry pro-
cess of SARS-CoV. In particular, inhibitors of the essential step of
SARS-CoV spike proteolysis, which, in cell lines at least, occurs in
the endosomes of target cells (Huang et al., 2006; Simmons et al.,
2005) were identified. It is hoped that compounds identified in
these assays to be specifically able to inhibit the endsomal proteo-
lytic processing of SARS-CoV Spike will be useful in animal studies
for determining whether the CTSL/endosomal route of entry or
surface protease-mediated fusion route is most important
in vivo. Many of these hits were dipeptide epoxyketones, and
had previously been reported to inhibit one of the coronavirus
proteases (Goetz et al., 2007). Two of these epoxyketones, WRR
182 and WRR 183, are isomers of each other. This affects their bio-
logical properties, with WRR 183 being 10-fold more potent
194 Y. Zhou et al. / Antiviral Research 92 (2011) 187–194against the SARS-CoV chymotrypsin-like protease. Nevertheless,
both compounds appear to inhibit SARS-CoV replication in vitro
with apparently similar abilities (Goetz et al., 2007). We demon-
strate here that WRR 182, but not 183, is highly active against
SARS-CoV spike-mediated entry. Thus, the antiviral properties of
these two isomers are explained. The R isomer likely acts through
the inhibition of CTSL activity. In contrast, the S isomer inhibits
replication due to the fact that it binds irreversibly to the 3Clpro
protease. Compounds capable of inhibiting both CTSL and 3Clpro
would target the virus at multiple steps of the life cycle, thus
increasing their efficiency. This would also likely lessen the
chances of drug resistance being established. With the WRR 495
compound we demonstrate that this is indeed possible. Unfortu-
nately, this compound, unlike the parental compounds, is highly
toxic. It is possible that this is due to WRR 495 becoming broadly
active against many cellular proteases, although we have not dem-
onstrated this. Nevertheless, WRR 495 represents the potential
that other, less toxic, dually active third generation compounds
can be developed.
In conclusion, this highly sensitive, rapid, and reproducible as-
say system has been successfully applied for the screening of entry
inhibitors of SARS-CoV. Moreover, it can be easily adapted to
screen for entry inhibitors of other viruses with careful selection
of matching partner virus envelopes of no interference. In particu-
lar, human coronaviruses together with other respiratory viruses,
such as metapneumovirus and parainfluenzavirus, can cause sig-
nificant morbidity and mortality, particularly among immunocom-
promised patients. HTS assays for entry inhibitors, such as the DEP
assay described here, should provide good lead candidates for anti-
viral drug development against SARS-CoV and other viruses.
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